First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level
Marina Konopleva, Todd Rosenblat, Alessandra Tosolini, Michael Zuurman et al.
Journal
Haematologica
Topics
Cutaneous lymphoproliferative disorders research
article
First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level
Marina Konopleva, Todd Rosenblat, Alessandra Tosolini, Michael Zuurman, David A. Rizzieri, Marco Herling, Kendra L. Sweet, Cristina Papayannidis, Naveen Pemmaraju, Eunice S. Wang, Anthony S. Stein, Andrew A. Lane, Muzaffar Qazilbash, Sumithira Vasu
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Roswell Park Comprehensive Cancer Center (US), Albert Einstein College of Medicine (US), Montefiore Medical Center (US), The University of Texas MD Anderson Cancer Center (US), Columbia University Irving Medical Center (US), Novant Health (US), Moffitt Cancer Center (US), Menarini Group (Italy) (IT), City of Hope (US), Dana-Farber Cancer Institute (US), Istituto di Ematologia di Bologna (IT), University Hospital Leipzig (DE), Herbert Irving Comprehensive Cancer Center, The Ohio State University (US)
Funders
U.S. Department of Defense, Amgen, Bristol-Myers Squibb, Pfizer, Astellas Pharma US, Sanofi, American Society of Clinical Oncology, Alexion Pharmaceuticals, Jazz Pharmaceuticals, MEI Pharma, CareDx, BeiGene, Incyte, Syndax Pharmaceuticals, Astellas Pharma, Menarini Group, Aptitude Health, National Institutes of Health, National Cancer Institute, Daiichi Sankyo Europe